Drugs / Onradivir
Onradivir
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT06248567 | Jan → Apr 2024 | impaired renal function disease | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06164431 | Nov → Dec 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06157450 | Oct → Nov 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05954624 | Jul → Nov 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05942365 | Jun → Jul 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05856513 | Jun → Jul 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05873426 | Mar → Apr 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05108051 | Nov 2020 → Mar 2021 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03679143 | Sep 2018 → Mar 2019 | influenza | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06656026 | Nov 2024 → Jun 2025 | influenza | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT04024137 | Dec 2019 → May 2020 | influenza | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07229807 | Nov → Dec 2025 overdue | influenza | Guangdong Raynovent Biotech Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07229547 | Nov 2025 → Dec 2026 expected | influenza | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07229820 | Nov → Dec 2025 overdue | influenza | Guangdong Raynovent Biotech Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04683406 | Dec 2020 → Apr 2023 | influenza | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Onradivir | “Onradivir is an influenza A virus RNA polymerase basic protein 2 inhibitor that is currently under development for the treatment of influenza A.” PMID 40757817 ↗ Aug 20253“BACKGROUND: Onradivir (ZSP1273) is a potent inhibitor of the PB2 subunit of influenza A virus (IAV) polymerase.” PMID 40489986 ↗ Jun 2025 “Onradivir (ZSP1273) is a novel anti-influenza A virus inhibitor.” PMID 38330975 ↗ Feb 2024 |
| Known as | [14C] ZSP1273 | “Drug: [14C] ZSP1273” NCT05873426 ↗ |
| Known as | ZSP1273 | “BACKGROUND: Onradivir (ZSP1273) is a potent inhibitor of the PB2 subunit of influenza A virus (IAV) polymerase.” PMID 40489986 ↗ Jun 2025 |
| Action | Inhibit | “ZSP1273 is a small-molecule anti-influenza drug targeting the RNA polymerase PB2 subunit of the influenza virus.” PMID 34654349 ↗ Nov 2021 |
| Modality | Small molecule | “ZSP1273 is a small-molecule anti-influenza drug” PMID 34654349 ↗ Nov 2021 |
| Route | Oral | “ZSP1273 tablets administered orally once daily under fasted condition” NCT03679143 ↗ |